CM
LGND icon

Capula Management’s Ligand Pharmaceuticals LGND Stock Holding History

Capula Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,900
Closed -$893K – 441
2023
Q3 		$893K Buy
14,900
+7,080
+91% +$466K 0.02% 245
2023
Q2 		$564K Buy
+7,820
New +$587K 0.01% 263
2023
Q1 		– Sell
-11,640
Closed -$778K – 835
2022
Q4 		$778K Buy
+11,640
New +$757K 0.01% 514

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capula Management's LGND Position: Q4 2023 in Review

Capula Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2023, closing a stake of 14,900 shares — an estimated $893K sold.

Capula Management first reported a position in LGND in Q4 2022 and held it in 3 quarters. The position peaked at $893K in Q3 2023. 211 funds tracked by Wall St. Rank hold LGND as of Q4 2023.

  • Capula Management reported no remaining Ligand Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Capula Management sold 14,900 Ligand Pharmaceuticals shares in Q4 2023, an estimated $893K.
  • Capula Management first reported a position in Ligand Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Capula Management's Ligand Pharmaceuticals position peaked at $893K in Q3 2023.
  • 211 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2023.

Based on Capula Management's 13F filing for Q4 2023, filed 12 Feb 2024.